Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

161 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Adoptive T-cell transfer and chemotherapy in the first-line treatment of metastatic and/or locally recurrent nasopharyngeal carcinoma.
Chia WK, Teo M, Wang WW, Lee B, Ang SF, Tai WM, Chee CL, Ng J, Kan R, Lim WT, Tan SH, Ong WS, Cheung YB, Tan EH, Connolly JE, Gottschalk S, Toh HC. Chia WK, et al. Among authors: toh hc. Mol Ther. 2014 Jan;22(1):132-9. doi: 10.1038/mt.2013.242. Epub 2013 Oct 17. Mol Ther. 2014. PMID: 24297049 Free PMC article. Clinical Trial.
Monocytic Myeloid-Derived Suppressor Cells Underpin Resistance to Adoptive T Cell Therapy in Nasopharyngeal Carcinoma.
Hopkins R, Xiang W, Marlier D, Au VB, Ching Q, Wu LX, Guan R, Lee B, Chia WK, Wang WW, Wee J, Ng J, Cheong R, Han S, Chu A, Chee CL, Shuen T, Podinger M, Lezhava A, Toh HC, Connolly JE. Hopkins R, et al. Among authors: toh hc. Mol Ther. 2021 Feb 3;29(2):734-743. doi: 10.1016/j.ymthe.2020.09.040. Epub 2020 Sep 30. Mol Ther. 2021. PMID: 33038324 Free PMC article.
Tailoring precision immunotherapy: coming to a clinic soon?
Han S, Shuen WH, Wang WW, Nazim E, Toh HC. Han S, et al. Among authors: toh hc. ESMO Open. 2020;5 Suppl 1(Suppl 1):e000631. doi: 10.1136/esmoopen-2019-000631. Epub 2020 Sep 30. ESMO Open. 2020. PMID: 33558033 Free PMC article. Review.
A phase I study of an adenoviral vector delivering a MUC1/CD40-ligand fusion protein in patients with advanced adenocarcinoma.
Tan TJ, Ang WXG, Wang WW, Chong HS, Tan SH, Cheong R, Chia JW, Syn NL, Shuen WH, Ba R, Kaliaperumal N, Au B, Hopkins R, Li X, Tan AC, Seet AOL, Connolly JE, Arkachaisri T, Chew V, Lajam ABM, Guo D, Chew MZW, Wasser M, Kumar P, Albani S, Toh HC. Tan TJ, et al. Among authors: toh hc. Nat Commun. 2022 Oct 28;13(1):6453. doi: 10.1038/s41467-022-33834-4. Nat Commun. 2022. PMID: 36307410 Free PMC article. Clinical Trial.
161 results